DEDIFFERENTIATED CHONDROSARCOMA
Clinical trials for DEDIFFERENTIATED CHONDROSARCOMA explained in plain language.
Never miss a new study
Get alerted when new DEDIFFERENTIATED CHONDROSARCOMA trials appear
Sign up with your email to follow new studies for DEDIFFERENTIATED CHONDROSARCOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for rare bone cancer: targeted drug shows promise
Disease control OngoingThis study tested a drug called vismodegib in 45 people with advanced chondrosarcoma, a rare bone cancer that has spread and is hard to treat. The goal was to see if the drug could shrink tumors or stop them from growing for at least 6 months. Researchers measured how many patien…
Matched conditions: DEDIFFERENTIATED CHONDROSARCOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 04:14 UTC
-
Immunotherapy shows promise for rare sarcomas in early trial
Disease control OngoingThis study tested a drug called atezolizumab in 27 people with rare cancers of the bone (chondrosarcoma) or soft tissue (clear cell sarcoma) that could not be removed by surgery or had spread. Atezolizumab is an immunotherapy that helps the body's immune system attack cancer cell…
Matched conditions: DEDIFFERENTIATED CHONDROSARCOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
Your own tumor cells could fight your cancer: new trial tests personalized T-Cell therapy
Disease control OngoingThis phase 2 trial tests a personalized cell therapy called LN-145 for people with certain advanced cancers (like ovarian, breast, thyroid, or bone cancers) that have not responded to treatment or have returned. The therapy uses a patient's own immune cells, taken from their tumo…
Matched conditions: DEDIFFERENTIATED CHONDROSARCOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 14, 2026 12:02 UTC